Karyopharm Therapeutics Inc KPTI

NAS: KPTI | ISIN: US48576U1060   14/11/2024
0,837 USD (-3,35%)
(-3,35%)   14/11/2024

3 september 2024 · Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

3 september 2024 · Karyopharm to Participate at Upcoming Investor Conferences · Persbericht

6 augustus 2024 · Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress · Persbericht

1 augustus 2024 · Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

31 juli 2024 · Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024 · Persbericht

1 juli 2024 · Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

3 juni 2024 · Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

1 juni 2024 · Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates · Persbericht

29 mei 2024 · Karyopharm to Participate at the Jefferies Global Healthcare Conference · Persbericht

8 mei 2024 · Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference · Persbericht

8 mei 2024 · Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029 · Persbericht

8 mei 2024 · Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress · Persbericht

2 mei 2024 · Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024 · Persbericht

1 mei 2024 · Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

24 april 2024 · Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting · Persbericht

1 april 2024 · Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

6 maart 2024 · Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences · Persbericht

1 maart 2024 · Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

29 februari 2024 · Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress · Persbericht

22 februari 2024 · Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024 · Persbericht

Mijn selecties